Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japanese multiple-ascending dose study of LY3841136 alone and with tirzepatide in obesity or overweight
jRCT2071230129Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Trial of eloralintide and tirzepatide in obesity and Overweight (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of participants with one or more serious adverse events considered related to study drug administration. Started Apr 2024; status: active, not recruiting.
02
Drugs
eloralintidetirzepatide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2071230129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230129.